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ABSTRACT
Objective Thiopurines are widely used as maintenance 
therapy in inflammatory bowel disease (IBD) but the 
evidence base for their use is sparse and their role 
increasingly questioned. Using the largest series reported 
to date, we assessed the long- term effectiveness of 
thiopurines in ulcerative colitis (UC) and Crohn’s disease 
(CD), including their impact on need for surgery.
Design Outcomes were assessed in 11 928 patients 
(4968 UC, 6960 CD) in the UK IBD BioResource initiated 
on thiopurine monotherapy with the intention of 
maintaining medically induced remission. Effectiveness 
was assessed retrospectively using patient- level data 
and a definition that required avoidance of escalation 
to biological therapy or surgery while on thiopurines. 
Analyses included overall effectiveness, time- to- event 
analysis for treatment escalation and comparison 
of surgery rates in patients tolerant or intolerant of 
thiopurines.
Results Using 68 132 patient- years of exposure, 
thiopurine monotherapy appeared effective for the 
duration of treatment in 2617/4968 (52.7%) patients 
with UC compared with 2378/6960 (34.2%) patients 
with CD (p<0.0001). This difference was corroborated 
in a multivariable analysis: after adjusting for variables 
including treatment era, thiopurine monotherapy was 
less effective in CD than UC (OR 0.47, 95% CI 0.43 to 
0.51, p<0.0001). Thiopurine intolerance was associated 
with increased risk of surgery in UC (HR 2.44, p<0.0001); 
with a more modest impact on need for surgery in CD 
(HR=1.23, p=0.0015).
Conclusion Thiopurine monotherapy is an effective 
long- term treatment for UC but significantly less effective 
in CD.
BACKGROUND
The thiopurine analogues azathioprine (AZA) and 
6- mercaptopurine (6MP) have held a long- standing 
place in the management of inflammatory bowel 
disease (IBD). In both ulcerative colitis (UC) and 
Crohn’s disease (CD) they are used for main-
taining remission in steroid- dependent or steroid- 
refractory disease.1–3 However, in recent years 
increasing emphasis has been placed on the known 
toxicity profile of thiopurines and, with increasing 
numbers of biological therapies including cheaper 
biosimilars available, some authorities are ques-
tioning their role.
Randomised controlled trials (RCTs) of thiopu-
rines in IBD from the 1970s to the 90s suggested 
efficacy in both UC and CD but, as was typical 
for RCTs of this era, the number of patients 
included was small and follow- up limited.4–10 More 
recently, the AZathioprine for Treatment or Early 
Crohn's disease in adults (AZTEC) and Résultat de 
Significance of this study
What is already known on this subject?
 ► Thiopurines are commonly used for 
maintenance of remission in steroid- dependent 
and steroid- refractory inflammatory bowel 
disease (IBD).
 ► Despite their widespread use, real- life data 
demonstrating durable effectiveness of 
thiopurines are sparse and are mostly derived 
from cohorts with modest numbers of patients 
and limited follow- up.
 ► In the era of cheaper biosimilar antitumour 
necrosis factor therapy, other biologics and 
newer small molecule therapies, the role of 
thiopurines in IBD management is increasingly 
being questioned.
What are the new findings?
 ► Using data from 11 928 patients with IBD 
treated with thiopurine monotherapy, we 
compared long- term effectiveness in ulcerative 
colitis (UC) and Crohn’s disease (CD) and their 
impact on need for surgery.
 ► Thiopurine monotherapy was effective for the 
duration of treatment in 52.7% of patients 
with UC but only 34.2% of patients with CD. 
On Kaplan- Meier analysis median duration 
on thiopurines in those in whom they were 
effective was 16 years for CD and 17 years for 
UC. Thiopurine monotherapy was more effective 
in UC than in CD in both prebiological and 
postbiological eras.
 ► Inability to tolerate thiopurines correlated with 
increased risk of surgery in UC (HR=2.44), with 
a more modest effect in CD (HR=1.23).
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l'Adjonction Précoce d'ImmunoDépresseurs (RAPID) strategy 
trials assessed the efficacy of azathioprine in maintaining 
remission when used very soon after diagnosis in CD. Neither 
demonstrated benefit of very early vs conventional use of thio-
purines.11 12
To gain further insight, single- centre retrospective studies 
in population- based cohorts have investigated the real- world 
outcomes of AZA and 6MP treatment in IBD and suggested 
40%–60% effectiveness.13–18 Again, however, the numbers 
involved have been relatively modest and/or the follow- up rela-
tively short, and few studies have compared effectiveness in UC 
versus CD.13 15–18
The effect of thiopurines in reducing surgery has also been 
studied. Early need for thiopurine clearly defines patients at 
increased risk for colectomy in UC,19 and the inability to tolerate 
thiopurine has also been associated with increased colectomy 
risk.20 21 In CD results have been more mixed. One French 
study suggested that thiopurines reduced need for surgery while 
another did not.22 23 In two UK studies reduced need for surgery 
correlated with increased thiopurine use—with a national cohort 
study showing 44% less surgery in patients on thiopurine for at 
least 6 months.24 25
There is little consensus regarding how long thiopurine treat-
ment should be continued. One retrospective series suggested 
4 years,26 but relapse following thiopurine cessation is common 
and response cannot always be recaptured.13
With more biologic and newer small molecule therapies now 
available some question the role of thiopurine monotherapy in 
IBD, asserting that the newer agents are more effective and safer. 
Biological therapies are, however, not without their own prob-
lems including non- response and particularly loss of response 
over time27–30; and the Janus- kinase inhibitor tofacitinib has 
also been associated with safety signals.31 32 Additionally, costs 
of biologic and JAK inhibitor therapies remain a bar in many 
healthcare settings.
Here, we present the outcomes of thiopurine use in the UK 
IBD BioResource—launched in 2016 as part of the UK National 
Institute for Health Research BioResource and encompassing 
a large cohort of ‘recallable’ patients on whom clinical details 
were ascertained at enrolment.33 We designed the study to inves-
tigate the long- term effectiveness of thiopurine monotherapy in 
UC and CD and explore the impact of thiopurine tolerance on 
the need for surgery.
METHODS
We undertook a retrospective analysis of the outcomes of thio-
purine treatment (AZA or 6MP) for patients with CD or UC in 
the IBD BioResource. Those with IBD- unclassified (IBDU) were 
included with UC. Patients were involved in the study design. 
All participants provided signed consent. The IBD BioResource 
is currently recruiting in 104 hospitals UK- wide. At a data lock 
taken on 14 January 2020, 31 481 patients had been enrolled.
Structured IBD phenotype data, including drug therapy 
outcomes and surgeries, were ascertained at IBD BioResource 
enrolment by research nurses and clinicians using a combination 
of case note review, patient interview and patient questionnaire. 
Periodic data validation exercises are undertaken with indepen-
dent reassessment of phenotype data. Most sites recruited unse-
lected consecutive patients with IBD attending clinic, the overall 
numbers recruited at each site varying according to duration of 
study setup and resources available.
For each subject in the current study, the outcome of historic 
or current AZA or 6MP treatment was assessed by the question 
‘Was the treatment effective?’, with responses being empirically 
classified into one of the following seven categories:
1. Yes.
2. No (on therapeutic dose >4 months—did not work).
3. Unable to assess (on therapeutic dose <4 months).
4. Unable to assess (unable to tolerate).
5. Worked for <12 months then lost response.
6. Worked for >12 months then lost response.
7. Response not known (eg, started antitumour necrosis factor 
(TNF) at same time, partial response only etc).
Our primary aim was to identify the proportion of patients 
treated with thiopurine monotherapy in whom this was deemed 
effective, satisfying both (A) response of ‘yes’ (option 1) to the 
question ‘Was the treatment effective?’ and (B) patient had not 
needed escalation to biologic therapy or IBD surgery for the 
duration of thiopurine therapy. Patients were excluded if the 
treatment response data were missing; and those started on anti 
TNF therapy at thiopurine initiation or undergoing surgery in the 
year of thiopurine initiation (where the drug may have been used 
as postsurgical prophylaxis) were excluded since we could not 
assess effectiveness of thiopurine monotherapy in these groups. 
UC patients who had undergone colectomy prior to thiopurine 
initiation were also excluded; as were cases where missing dates 
did not allow us to confirm whether biological therapy/surgery 
overlapped the indicated period of thiopurine monotherapy.
The effectiveness of thiopurine monotherapy was also inves-
tigated in terms of time from initiating thiopurine to require-
ment for treatment escalation with biological therapy or surgery, 
whichever occurred first.
To investigate whether thiopurine therapy has an impact on 
need for surgery in UC and CD, the time from treatment initia-
tion to surgery was compared between patients able to tolerate 
thiopurine versus those unable to tolerate thiopurine. Only 
patients who were deemed unable to tolerate any thiopurine at 
any dose were labelled as ‘intolerant’ in this analysis (eg, this 
group did not include people unable to tolerate AZA but able to 
tolerate 6MP; or those able to tolerate thiopurine following dose 
reduction±concomitant allopurinol).
Descriptive statistics of the clinical characteristics were calcu-
lated, with continuous variables presented as medians (25th–75th 
percentile); and categorical variables as frequencies and percent-
ages. Duration of thiopurine monotherapy was calculated from 
start to end of treatment or censored for participants who were 
still on thiopurine monotherapy at the time of data lock, and 
summarised using Kaplan- Meier estimates. Adverse event inci-
dence was compared between UC and CD by X2 testing. The 
Cochran- Mantel- Haenszel (CMH) test was applied to compare 
the effectiveness of thiopurine monotherapy between UC and 
CD, using stratified treatment initiation time periods grouped 
5 yearly. Comparison of the effectiveness of thiopurine between 
Significance of this study
How might it impact on clinical practice in the foreseeable 
future?
 ► In re- evaluating their current role in inflammatory bowel 
disease management, our study suggests that thiopurine 
monotherapy is effective in maintaining long- term clinical 
remission in ulcerative colitis. In Crohn’s disease, however, 
thiopurines are less effective as monotherapy particularly 
where there is perianal involvement. Here, there should 
be a lower threshold for biological therapy from outset±in 
combination with thiopurine.
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UC and CD was also assessed using a multivariable logistic regres-
sion with covariates of age at diagnosis, gender, smoking history, 
treatment era and time from diagnosis to thiopurine initiation. 
Kaplan- Meier methods were applied for the time to treatment 
escalation with biological therapy or surgery. The differences of 
distributions between UC and CD were compared using the log- 
rank test. Logistical regression models were applied to explore 
the correlation between the thiopurine monotherapy effective-
ness and the clinical characteristics within UC and CD using 
the same covariates as above but also including disease loca-
tion. Similar analyses were performed using the Cox regression 
models for the time to surgery outcome. Due to the large size 
of the dataset, a conservative prespecified p value threshold of 
less than 0.005 was considered statistically significant. Statistical 
analyses were performed using the SAS V.9.4.
RESULTS
Patient population
Of the 31 481 participants in the IBD BioResource at the data 
lock, 17 921 (56.9%) had been treated with a thiopurine for 
IBD (71.9% with CD; 43.8% with UC), either as monotherapy 
or combined with anti- TNF therapy. A total of 11 928 met the 
criteria for assessment of the effectiveness of thiopurine mono-
therapy (6960 CD and 4968 UC (including 251 IBDU)). Here-
after all analyses refer to this cohort of 11 928 subjects (figure 1).
Patient characteristics are presented in table 1. Median age at 
CD/UC diagnosis was 26/33 years. Median time from diagnosis 
to data capture was 12 years (total follow- up 99 555 patient- 
years/total thiopurine exposure 40 807 patient- years) for CD 
and 10 years (total follow- up 60 413 patient- years/thiopurine 
exposure 27 325 patient- years) for UC.
Thiopurine treatment and tolerability
Of the 11 928 subjects treated with thiopurine 11 239 (94.2%) 
received AZA and 2698 (22.6%) 6MP; this included 2009 
(16.8%) who received both at different time points. A total of 
2984 (26.6%) subjects treated with AZA were unable to tolerate 
it and had to stop. Of those exposed only to 6MP, 138/689 
(20.0%) experienced an adverse effect and consequently stopped. 
Of 11 928, 2482 (20.8%) could not tolerate either thiopurine at 
any dose. A total of 1327 patients were exposed to both AZA 
and 6MP after intolerance of their first thiopurine, of whom 
640/1327 (48.2%) were able to tolerate the second thiopurine.
Median overall duration of thiopurine treatment was 8 (1–25) 
years for CD and 9 (1–24) years for UC. Median time from 
diagnosis to thiopurine initiation was 2 years for both CD and 
UC, with 46.7% starting thiopurine within 2 years of diagnosis 
(figure 2). A total of 2905 (41.7%) of those with CD and 1377 
(27.7%) with UC received biological therapies after attempted 
treatment with thiopurine monotherapy.
Adverse events were consistent with those reported previously 
(table 1). Nausea/vomiting and deranged liver function tests 
were the most common. Permanent thiopurine discontinuation 
due to pancreatitis was more common in CD than UC (2.7% vs 
1.2%, X2 p<0.0001), whereas treatment- limiting hepatotoxicity 
was more common in UC (3.2% vs 2.1% in CD, p=0.0003).
Effectiveness of thiopurine monotherapy
Of 11 928 subjects with IBD treated with thiopurine mono-
therapy, it was reported to have been effective, without the 
need for escalation to biologic therapy or need for surgery for 
the duration of thiopurine treatment, in 4995 (41.9%). It was 
effective for UC in 2617/4968 (52.7%) of patients; and a lower 
proportion of patients with CD: 2378/6960 (34.2%).
Using the CMH test to stratify by treatment initiation era, thio-
purine monotherapy appeared more effective in UC than CD for 
all 5- year chronological periods (RR 1.40, 95% CI 1.35 to 1.45, 
p<0.0001) (online supplementary figure 1). The absolute effec-
tiveness of thiopurine monotherapy appeared to decrease in UC 
and increase in CD in more recent cohorts (online supplemen-
tary figures 2 and 3). We incorporated treatment era along with 
other possible confounding factors in a multivariable logistic 
regression analysis. This again demonstrated that thiopurine 
monotherapy was less effective in CD than UC (OR 0.47, 95% 
CI 0.43 to 0.51, p<0.0001), after adjusting for era of starting 
thiopurines, time from diagnosis to thiopurine initiation, age at 
diagnosis and smoking history (table 2).
Clinical characteristics and response to thiopurine 
monotherapy
For CD, in a multivariable analysis after controlling for 
confounding factors, thiopurine therapy appeared more effective 
in patients with colonic as opposed to ileocolonic involvement 
(OR 1.60, 95% CI 1.38 to 1.86, p=0.002) and older patients 
(1.01 per year, 95% CI 1.01 to 1.02, p<0.0001). By contrast, 
treatment initiation ≤1 year after IBD diagnosis (OR 0.69, 95% 
CI 0.60 to 0.78, p<0.0001) and perianal disease (OR 0.70, 95% 
CI 0.61 to 0.80, p<0.0001) were associated with lower thio-
purine effectiveness (table 3). No correlation was found with 
gender or smoking history.
For UC, proctitis was associated with higher effectiveness 
(OR=1.56 vs extensive disease, 95% CI 1.23 to 1.98, p=0.0002) 
(table 3).
Duration of effect
For participants in whom thiopurine monotherapy was deemed 
effective, over 70% were still on this treatment at the time of our 
data lock. Median treatment duration on Kaplan- Meier analysis 
Figure 1 Study flow chart.
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of this group was 16 (95% CI 15 to 19) years for CD and 17 
(95% CI 15 to 20) years for UC (online supplementary figure 4).
We performed a time- to- event analysis for patients on thio-
purine monotherapy assessing time to escalation to biolog-
ical therapy or surgery. A total of 11 189 (6464 CD, 4725 
UC) participants were included with 739 excluded due to 
missing data. Of patients continuing thiopurine 4907 (44%) 
required treatment escalation after a median time of 4 (95% 
CI 4 to 5) years in CD and 12 (95% CI 11 to 13) years in 
UC (p<0.0001 for log- rank test) (figure 3). This remained 
significant after adjusting for treatment period and clinical 
characteristics using the Cox regression model (p<0.0001). 
Table 1 Demographic and clinical characteristics and adverse reactions in the 11 928 patients in the IBD BioResource treated with thiopurine 
monotherapy
CD UC
Age at diagnosis 26(19–39) 33 (24–45)
Gender     
  Male 3181 (45.8%) 2615 (52.7%)
  Female 3768 (54.2%) 2347 (47.3%)
Smoking status at diagnosis     
  Never smoked 3387 (51.9%) 2538 (54.5%)
  Smoking at diagnosis 2236 (34.2%) 673 (14.5%)
  Ex- smoker 909 (13.9%) 1443 (31.0%)
Disease location     
CD     
  Ileal 2487 (37.0%)   
  Colonic 1747 (26.0%)   
  Ileo- colonic 2413 (35.9%)   
  Exclusive upper GI Crohn’s 75 (1.1%)   
  Perianal involvement 1989 (30.2%)   
UC     
  Proctitis (E1)   379 (8.5%)
  Left sided (E2)   2143 (48.3%)
  Extensive (E3)   1917 (43.2%)
Tolerated thiopurine 5382 (77.3%) 4064 (81.8%)
Adverse reactions (X2 test between groups unable to 
tolerate thiopurine)
Whole cohort Intolerant group (had to 
discontinue thiopurines)
Whole cohort Intolerant group (had to 
discontinue thiopurines)
  N (%) N (%) N (%) N (%)
Abdominal pain (p=0.04) 216 (3.2) 134 (2.0) 115 (2.3) 71 (1.5)
Deranged LFT (p=0.0003) 326 (4.8) 146 (2.1) 369 (7.5) 158 (3.2)
Flu- like symptoms (p=0.01) 177 (2.6) 99 (1.5) 119 (2.4) 70 (1.4)
Leucopenia (p=0.45) 145 (2.1) 38 (0.6) 123 (2.5) 32 (1.4)
Nausea/vomiting (p=1.32) 793 (11.6) 434 (6.4) 563 (11.5) 286 (5.8)
Pancreatitis (p<0.0001) 235 (3.4) 182 (2.7) 78 (1.6) 57 (1.2)
Other (p=0.53) 1490 (21.4) 712 (10.2) 1056 (21.6) 488 (10)
CD, Crohn’s disease; IBD, inflammatory bowel disease; LFT, liver function tests; UC, ulcerative colitis.
Figure 2 Time (years) from IBD diagnosis to thiopurine initiation in 
the 11 928 subjects. IBD, inflammatory bowel disease.
Table 2 Multivariable analysis of factors affecting thiopurine 
monotherapy effectiveness
OR 95% CI P value
Diagnosis   
  CD 0.47 0.43 to 0.51 <0.0001
  UC 1 Referent
Treatment period 1.06 1.02 to 1.09 0.0008
Time from diagnosis to thiopurine initiation 1.02 1.01 to 1.02 <0.0001
Age at diagnosis 1.01 1.01 to 1.02 <0.0001
Gender   
  Female 1.06 0.97 to 1.14 0.19
  Male 1 Referent
Smoking history   
  No 1.12 1.03 to 1.22 0.007
  Yes 1 Referent
Significant p values shown in bold.
CD, Crohn’s disease; UC, ulcerative colitis.
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Of patients initiated on thiopurine monotherapy, at 1 and 
3 years 69% and 54% of those with CD, and 76% and 69% 
with UC, respectively, remained on thiopurine and had not 
required treatment escalation to biological therapy or surgery 
(online supplementary table 1).
Effect of thiopurine therapy on surgery in UC
Of the 4968 patients with UC in whom thiopurine mono-
therapy was assessed, 219 (4.4%) had required colec-
tomy—92 for acute severe colitis, 92 for medically refractory 
disease, 12 for cancer/dysplasia and 23 with reasons not 
documented. We analysed the proportion of patients 
requiring colectomy according to tolerance of thiopurine 
treatment: 63/904 (7.0%) of patients intolerant of thiopurine 
required colectomy compared with 156/4064 (3.8%) of those 
able to tolerate thiopurines. Time to colectomy was shorter 
in individuals unable to tolerate vs able to tolerate thiopurine 
(figure 4, log- rank <0.0001). In a Cox proportional hazards 
model, the HR for colectomy was 2.44, 95% CI 1.71 to 3.50 
(p<0.0001) in individuals unable to tolerate thiopurine. 
Figure 4 Kaplan- Meier plot showing the proportion of patients 
with UC not requiring colectomy relative to time since initiation of 
thiopurines, stratified by ability to tolerate thiopurines. Patients unable 
to tolerate thiopurine had a significantly shorter time to colectomy (log- 
rank <0.0001). UC, ulcerative colitis.
Table 3 Regression analysis of factors influencing thiopurine effectiveness in CD and UC patients
CD UC
Univariable Multivariable Univariable Multivariable
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR P value
Age at diagnosis 1.02 (1.01 to 1.02) <0.0001 1.01 (1.01 to 1.02) <0.0001 1 (1.00 to 1.01) 0.49     
Gender   0.08       0.72     
  Male 1.09 (0.99 to 1.20)       1.02 (0.91 to 1.14)       
  Female Referent       Referent       
Smoking history   0.34       0.12     
  No 0.95 (0.86 to 1.05)       1.01 (0.98 to 1.23)       
  Yes Referent       Referent       
Treatment era     1.2 (1.14 to 1.25) <0.0001     0.88 (0.83 to 0.93) <0.0001
Time from diagnosis to 
thiopurine initiation
                
  <1 year 0.72 (0.64 to 0.82) <0.0001 0.69 (0.60 to 0.78) <0.0001 0.87 (0.76 to 1.0) 0.36     
  ≥1 and <2 years 0.92 (0.80 to 1.06) 0.24 0.81 (0.70 to 0.95) 0.81 0.86 (0.74 to 1.0) 0.27     
  ≥2 years Referent               
Disease location (CD)                 
  Ileal 1.28 (1.14 to 1.45) 0.57             
  Colonic 1.61 (1.42 to 1.84) 0.008 1.6 (1.38 to 1.86) 0.002         
  Exclusive upper GI 1.53 (0.96 to 2.46) 0.44             
  Ileo- colonic Referent               
Perianal involvement                 
  Yes 0.67 (0.59 to 0.75) <0.0001 0.7 (0.61 to 0.80) <0.0001         
  No Referent               
Disease location (UC)                 
  Proctitis (E1)         1.47 (1.17 to 1.84) 0.0006 1.56 (1.23 to 1.98) 0.0002
  Left sided (E2)         1.01 (0.89 to 1.14) 0.01     
  Extensive (E3)         Referent       
Significant p values shown in bold.
CD, Crohn’s disease; UC, ulcerative colitis.
Figure 3 Kaplan- Meier plots of time during which thiopurine 
monotherapy was effective in UC and CD, without requirement for 
treatment escalation (p<0.0001 for log- rank test). CD, Crohn’s disease; 
UC, ulcerative colitis.
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Extensive colitis and younger age at diagnosis also correlated 
with increased risk of colectomy (table 4).
Treatment with biological therapies also differed between 
groups. Of patients with UC who were unable to tolerate thiopu-
rines 365/904 (40.4%) subsequently received biological therapy, 
compared with 1012/4064 (24.9%) of those able to tolerate 
thiopurines (p<0.0001). Thus, patients with UC unable to 
tolerate thiopurines required earlier colectomy despite increased 
use of biological therapies.
Effect of thiopurine therapy on surgery in CD
Unlike with UC, patients with CD with a surgical procedure 
prior to thiopurine initiation were included in this analysis, 
because reoperation is common in the natural history of CD. 
In total, 3077/6960 patients (44.2%) treated with thiopurine 
monotherapy underwent surgery for CD. 1517/6960 (21.8%) 
had an operation after thiopurine initiation.
A total of 1578 patients with CD could not tolerate thiopurine 
treatment. Their time to surgery was modestly shorter compared 
with the 5382 patients with CD able to tolerate thiopurines in 
the Kaplan- Meier analysis (log- rank=0.002 - figure 5). Inability 
to tolerate thiopurine was associated with risk of surgery in a 
Cox proportional hazards model (HR 1.23, 95% CI 1.08 to 
1.40, p=0.0015). The latter also identified reduced risk of 
surgery in patients with CD where only the colon was involved 
(table 5), as previously reported.
Use of biological therapy again differed between the two 
groups. 782/1578 (49.6%) patients with CD unable to tolerate 
thiopurines were escalated to biological therapy, compared with 
2123/5382 (39.4%) of patients able to tolerate these drugs 
(p<0.0001).
DISCUSSION
Thiopurines are commonly used in the treatment of IBD, but 
their role is increasingly questioned given the ever- expanding 
range of biologic therapy options, the introduction of modestly 
priced biosimilar anti- TNF, increasing concerns about the toler-
ability and safety of thiopurines and a lack of data regarding 
efficacy.11 12
We report the first large- scale study in the biological era 
assessing clinical practice and patient- level outcomes of IBD 
treatment with thiopurines. Long- term outcome data remain 
sparse for all IBD treatments, but durability is key in therapy 
planning for CD and UC given their chronic nature. The most 
striking finding from our study was the evidence that thiopu-
rines provided an effective long- term treatment for 52.7% of 
patients with UC, without need for escalating to biological 
therapy or surgery; but that durable effectiveness in CD was 
lower at 34.2%. These results include all individuals in whom 
AZA and 6MP were initiated and do not exclude those intol-
erant of thiopurines.
Our finding of increased effectiveness for thiopurine mono-
therapy in UC compared with CD was consistent when we 
performed a multivariable logistic regression correcting for 
Table 4 Cox regression analysis of factors affecting time to 
colectomy in UC patients
P value HR 95% CI
Able to tolerate thiopurines     
  No <0.0001 2.44 1.71 to 3.50
  Yes   1 Referent
Age at diagnosis <0.0001 0.99 0.96 to 0.99
Treatment period 0.46 1.06 0.91 to 1.23
Time from diagnosis to thiopurine 
initiation
0.002 0.96 0.93 to 0.98
Gender     
  Female 0.28 0.84 0.60 to 1.16
  Male   1 Referent
Smoking history     
  No 0.48 0.88 0.62 to 1.25
  Yes   1 Referent
Disease location     
  Proctitis (E1) 0.54 0.75 0.30 to 1.90
  Left sided (E2) Referent 1 Referent
  Extensive (E3) <0.0001 2.58 1.78 to 3.72
UC, ulcerative colitis.
Figure 5 Kaplan- Meier plot showing the proportion of patients with 
CD not requiring surgery relative to time since initiation of thiopurines, 
stratified by ability to tolerate thiopurines. Patients unable to tolerate 
thiopurine had a significantly shorter time to surgery (log- rank=0.002). 
CD, Crohn’s disease.
Table 5 Cox regression analysis of factors affecting time to surgery 
in CD patients
P value HR 95% CI
Able to tolerate thiopurines   
  No 0.0015 1.23 1.08 to 1.40
  Yes 1 Referent
Treatment period 0.92 1 0.96 to 1.05
Time from diagnosis to thiopurine 
initiation
0.0001 0.99 0.98 to 0.99
Age at diagnosis 0.0001 0.99 0.986 to 0.995
Gender   
  Female 0.05 1.11 1.00 to 1.24
  Male 1 Referent
Smoking history   
  No 0.06 0.89 0.80 to 1.01
  Yes 1 Referent
Disease location   
  Ileal 0.058 1.13 0.99 to 1.27
  Colonic <0.0001 0.5 0.43 to 0.58
  Exclusive upper GI 0.46 1.22 0.71 to 2.07
  Ileocolonic 1 Referent
Perianal involvement   
  No <0.0001 0.52 0.47 to 0.59
  Yes 1 Referent
Significant p values shown in bold.
CD, Crohn’s disease.
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baseline differences (CD vs UC, OR 0.47, 95% CI 0.43 to 0.51). 
The same conclusion was obtained when any missing covari-
ates were imputed (estimated OR 0.50, 95% CI 0.46 to 0.54). 
Perianal involvement is an established risk factor for thiopurine 
treatment failure, corroborated by the results of our study (OR 
0.70, 95% CI 0.61 to 0.80). We undertook a sensitivity analysis 
testing whether the lower effectiveness in CD overall might be 
due to poor response in the perianal group. Even after excluding 
patients with perianal CD, thiopurine monotherapy remained 
less effective in patients with purely luminal CD as compared 
with those with UC (OR 0.52, 95% CI 0.47 to 0.56, p<0.0001). 
In a further analysis using a different definition of effective-
ness, which considered time to treatment escalation or surgery, 
we again found evidence of increased thiopurine effectiveness 
in UC compared with CD (figure 3). Finally, the protective 
effect against surgery in those tolerant of thiopurines compared 
with those intolerant was again more apparent in UC than CD 
(figures 4 and 5).
Since treatment landscapes and expectations have changed 
over time, we wanted to understand whether treatment era 
might have influenced reported outcomes. While treatment era 
was a significant covariate in our multivariable model, thiopu-
rines appeared more effective in UC than CD in all time periods 
(online supplementary figure 1), including during the periods 
after the arrival of licensed and reimbursed biologics. The 
apparent trend to reduced comparative effectiveness of thiopu-
rine monotherapy in UC versus CD over time was mainly driven 
by seeming increased effectiveness in CD (online supplemen-
tary figure 3). Several factors might contribute to this, some of 
which reflect the potential biases inherent in data derived retro-
spectively for a cohort study such as ours. In CD, which often 
progresses to needing surgery over time (eg, for development of 
strictures), duration of follow- up for patients recently started on 
thiopurine may have been insufficient for the need for surgery to 
accrue. Requirement for surgery indicated ‘ineffective’ treatment 
in the definition we used in our primary effectiveness analysis—
hence potentially inflating apparent effectiveness in recently 
started cohorts compared with cohorts on therapy for longer. 
In UC the opposite selection bias may have impacted, with 
under- representation in medical clinics (where most IBD BioRe-
source participants are recruited) of patients that had undergone 
colectomy years before, leading to inflation of apparent effec-
tiveness rates of thiopurine among those still attending. Finally, 
in the postbiological era patients and physicians may have 
altered expectations and be more ready to escalate therapy for 
side effects or delayed treatment action of thiopurines. In this 
context, although changes in UK reimbursement rules greatly 
improved access to biologics for UC after 2015, any changes 
in apparent effectiveness of thiopurine monotherapy after this 
date were modest (online supplementary figure 2). In summary, 
although we recognise the inherent limitations in our retrospec-
tive data series, we do not believe that any of the potential biases 
we have identified would explain our key finding of increased 
effectiveness in UC compared with CD.
Our multivariable analysis also identified specific patient 
subgroups most likely to respond to treatment with thiopurine 
monotherapy. These included older patients with more distal UC, 
or colonic (but not perianal) CD. For both UC and CD patients 
starting treatment longer after diagnosis responded better. This 
may reflect disease severity bias as patients with aggressive 
disease often escalate through thiopurines and biologics soon 
after diagnosis.
Data relating to the proportion of patients with IBD being 
treated with thiopurines are lacking. The IBD BioResource 
recruits in over 100 hospitals covering the spectrum from small 
district hospitals to large university centres. In this cohort, 
broadly representative of UK hospital practice, it is clear that 
thiopurines have been and continue to be widely used—in 
43.8% of patients with UC and 71.9% with CD. Interestingly 
the proportion on thiopurines does not appear to have reduced 
significantly with increasing biological therapy availability (data 
not shown). National Institute for Health and Care Excel-
lence recommendations may be relevant to this, as in UK prac-
tice all patients escalated to biologics should have first trialled 
immunomodulators.
A key question with any drug in IBD is when and whether 
to stop treatment in those achieving remission. Previous small 
studies considered thiopurine cessation appropriate after 4 years 
but relapse following cessation is common.13 26 Strikingly, in the 
current study, most patients in whom treatment was deemed 
effective were still on thiopurines at the data lock, with a median 
treatment duration of 16 (CD) and 17 (UC) years on Kaplan- 
Meier analysis (online supplementary figure 4). It seems that 
thiopurines are continued for prolonged periods where they 
are proving effective despite well- documented concerns about 
increased risk of skin cancers and lymphoma long term.34
Early RCTs of thiopurines in IBD included only modest numbers 
of patients and short follow- up—and one or both of these limita-
tions also apply to subsequent ‘real- world’ studies.4–10 13–15 17 18 A 
recent meta- analysis of 489 CD subjects showed remission rates 
of 73% on AZA, but also 62% in the placebo group (RR 1.19, 
95% CI 1.05 to 1.34) with limited follow- up of 6–18 months.1 
Jharap et al reported thiopurine effectiveness of 48% for CD 
and 38% for UC in two 8 years intercept cohorts totaling 366 
patients.15 However, effectiveness was defined as clinical remis-
sion in patients still on thiopurine at 5 years, regardless of 
surgery or anti- TNF commencement. Another ‘real- world’ study 
from Oxford undertook retrospective case notes review on 622 
thiopurine- experienced IBD patients.13 Relapse was defined as 
need for steroids or surgery, and the assessment of effectiveness 
required at least 6 months on azathioprine, therefore, patients 
unable to tolerate the medication were excluded from this anal-
ysis. Thiopurines appeared effective in 45% of patients with CD 
and 58% with UC but average treatment duration was less than 
2 years.
RCTs of thiopurine in UC are even more limited. A meta- 
analysis of six studies included only 124 patients and suggested 
60% remission on thiopurine vs 37% on placebo or 5 amin-
osalicylates.35 Observational studies have typically included 
100–250 patients and reported benefit in 40%–60%.13 15 36–38
With 11 928 participants contributing 68 132 years of thio-
purine exposure data, the large size of our study should under-
score confidence in our findings. Nevertheless, our study clearly 
also has limitations. Necessarily for a large- scale retrospective 
study we used a pragmatic, but non- validated definition of effec-
tiveness which may not always equal remission. This required a 
clinical judgement regarding effectiveness and also persistence 
on thiopurine without need for biological escalation or surgery. 
Studies frequently now use persistence on drug as a marker of 
continued effectiveness, so in this regard our definition was 
more rigorous than many.39 40
Other limitations include the lack of assessment of mucosal 
healing for example by calprotectin assay or endoscopy data. The 
IBD BioResource is a hospital- based programme, and hence may 
be skewed towards individuals with more severe disease. This 
will have inflated the proportion of patients with IBD who have 
been treated with thiopurines and indeed biologics compared 
with population cohorts. In addition, all patients on thiopurines, 
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regardless of dose, were included. We have not captured data on 
thiopurine dosing or metabolite monitoring to identify patients 
in whom thiopurines were ineffective due to underdosing. Nor 
have full data on concomitant use of 5- ASA, or the need for 
corticosteroids or hospitalisation been captured. However, we 
feel it unlikely that 5- ASA use alone would explain the differ-
ences we observed; and in UK practice recurrent need for either 
corticosteroids or hospitalisation in patients established on thio-
purine would conventionally mandate escalation to biologic 
therapy or surgery—data which we did capture to signal lack of 
thiopurine effectiveness.
In UC, we observed a colectomy rate of 4.4% in individuals 
in whom thiopurine monotherapy was tried (and 5.1% in all 
patients with UC in the IBD BioResource). Although lower 
than many historic series,41–45 two recent British cohorts have 
reported similar rates. Chhaya et al reported that in a popu-
lation cohort of 8673 incident UC patients (1766 receiving 
thiopurines) 5.5% underwent colectomy,20 while Alexakis et al 
reported a 4.9% crude colectomy rate.46 In common with the 
former study, we sought evidence that thiopurines reduced UC 
colectomy risk. By comparing patients able to tolerate the medi-
cation with those who had been treated with thiopurine but 
were unable to tolerate it we controlled for the impact of disease 
severity on colectomy risk (selection bias). Our regression anal-
ysis showed a significantly earlier need for surgery in thiopurine- 
intolerant patients (figure 4), with an HR of 2.44 for risk of 
earlier colectomy (table 4). Consistent with other studies our 
data also showed higher colectomy risk in extensive versus distal 
UC. Chhaya et al identified a 71% reduction colectomy risk in 
1766 individuals with UC treated with thiopurine for at least 12 
months compared those on it for less than 12 months. Similar 
conclusions were drawn from a population- based study from 
Manitoba and a recent Scandinavian hospital cohort (reduction 
in absolute colectomy risk from 29% to 19.5%).20 21 41
Evidence in our study for the benefits of thiopurine therapy 
on the need for surgery in CD was more modest than in UC 
(figure 5 and table 5). We observed a lower risk of abdom-
inal surgery in older patients and in those with colonic disease 
without small bowel involvement, as previously reported.13 
In two recent studies, one a Danish CD population cohort of 
13 185 patients, thiopurine use did not appear to affect surgical 
rates46 47; but others suggest that thiopurines do reduce surgery 
in CD—for example, a UK population cohort study by Chatu et 
al and data from Hungary.25 48 Our data revealed the same direc-
tion of effect as the earlier UK study but more modest benefit 
in reducing surgery. Substantial differences in study design may 
account for this difference, such as patient selection (population 
vs hospital- based cohorts), capturing of surgery (unlike Chatu 
et al we included all IBD- related surgery including perianal CD 
surgery) and eras examined (we included patients diagnosed 
pre-1989 and post-2005). In a 2014 meta- analysis, thiopurine 
use correlated with a 40% reduced risk of resectional surgery 
in CD.49 However, asymmetry was observed in the funnel plot, 
with studies showing no benefit of thiopurines in surgery being 
under- represented. Additionally, this meta- analysis did not 
include the large, negative Danish study published shortly after.47
CONCLUSION
The current study provides robust real- world evidence from 
the large UK IBD BioResource dataset that thiopurine mono-
therapy is an effective long- term treatment for UC. However, it 
appears less effective in CD (OR=0.47) particularly where there 
is perianal involvement. Previous studies showed no benefit of 
thiopurines initiated very soon after CD diagnosis (with consis-
tent data in our study),11 12 and there is clear evidence from 
trials such as SONIC for improved efficacy when thiopurines 
are combined with infliximab for the treatment of CD.50 Given 
recent substantial reductions in the cost of biosimilar anti- TNF 
therapy, and the evidence presented regarding the relative lack 
of durable effectiveness of thiopurine monotherapy in CD, there 
is perhaps a need to re- evaluate treatment strategies. For patients 
with anything more than mild to moderate CD thiopurines 
should perhaps be viewed primarily as an adjunct to anti- TNF 
therapy.
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